Zydus Lifesciences gets USFDA nod to produce prostate cancer treatment drug

Zydus Lifesciences Ltd has received final approval from the USFDA to manufacture 60 mg Apalutamide tablets for prostate cancer treatment. These tablets will be produced at their Ahmedabad facility. Apalutamide, an androgen receptor inhibitor, is intended for metastatic castration-sensitive prostate cancer and had annual sales of USD 1,099.8 million in the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/krVHsBX
via IFTTT